APIM receives second seed round for chemotherapy enhancer
This article was originally published in Scrip
Executive Summary
Trondheim, Norway-based APIM Therapeutics has received a second six-digit (Euro) tranche of funding from Sarsia Seed, a Norwegian seed investor focusing on life sciences, to further develop its lead drug candidate, ATX-101, as an enhancer of first-line chemotherapies. Sarsia made its first investment of NOK3.5 million (€440,000) into the project last May.